Navigation Links
BioMS Medical Announces 2008 Year End Results
Date:3/17/2009

its primary endpoint at the end of the trial. Based on the DSMB decision, Eli Lilly and Company (Lilly) provided a US $10 million milestone payment to BioMS as part of the terms of the licensing and collaboration agreement. BioMS anticipates MAESTRO-01 will be completed in 2009 with results from the trial expected in the second half of this year. - MAESTRO-02: Eligible patients who have successfully completed MAESTRO-01 may choose to receive dirucotide on an un-blinded basis in this open-label follow-on study. To date, approximately 95% of the eligible patients who have successfully completed the MAESTRO-01 trial have enrolled in this follow-on study. - MAESTRO-03: Enrollment was initiated in June, 2007 and completed on August 1, 2008 for this pivotal U.S. phase III trial of approximately 510 SPMS patients at 67 sites across the U.S. To date, the DSMB has conducted three reviews of the data from this trial and recommended it continue. The next DSMB review is expected to take place in the second quarter of fiscal 2009. - MINDSET-01: MINDSET-01 was a randomized, double-blind study that recruited 218 relapsing-remitting MS patients at 24 trial sites in six countries across Europe. BioMS recently announced that the top line results of this exploratory study did not meet its primary endpoint of effecting annualized relapse rate or associated secondary magnetic resonance imaging (MRI) endpoints. Dirucotide did meet certain secondary endpoints related to the progression of the disease, including mean change from baseline in the EDSS and the MS Functional Composite (MSFC) score. Changes in EDSS and MSFC are primary and secondary outcomes in the ongoing phase III SP
'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... the first time, chemists have succeeded in measuring vibrational ... resolution. The study reveals how vibration of a single ... , The study was performed at the University ... the University of Jyvskyl works as a visiting fellow ... the study. The second team was lead by Professor ...
(Date:8/20/2014)... Mass. , Aug. 20, 2014  Decision Resources Group finds ... , Russia , India ... $1.6 billion in 2013, roughly equal to the size of ... however, the BRIC market will experience much faster growth as a ... aging population. Other key findings from Decision Resources Group,s ...
(Date:8/20/2014)... Not long ago, it was more ... performed late in the development cycle – even after ... trends suggest that, like many things GxP, expectations for ... years, multiple drug sponsors have been required by authorities ... during phase I/II. It’s not only clinical trial material ...
(Date:8/20/2014)... WriteResult®, a leading provider of Electronic Patient ... its myPROpad™ ePRO tablet with the addition of a ... most widely used and well-respected Patient Reported Outcome (PRO) ... is used during clinical trials and in other health ... used to demonstrate Health-Related Quality of Life outcomes (HRQoL) ...
Breaking Biology Technology:Seeing a molecule breathe 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2EQ-5D™ Assessment Now Available for iPad 2
... 14 For 88 percent of,companies, front-line and ... cover a variety of development skills but focus,strongly ... Yet only half of executive-level sales leaders ... leadership development and,training, according to a member-driven research ...
... April 14 eResearchTechnology,Inc. (eRT), (Nasdaq: ... today their,alliance to provide integrated Cardiac Safety ... worldwide., eResearchTechnology is a leading provider ... other services,to the pharmaceutical, biotechnology, medical device, ...
... Corporation,(Pink Sheets: PHCP) (the "Company") clarified today that ... connection with,market transactions and are a valid representation ... This clarification was issued in response to,information from ... firms,will not negotiate Phlo common stock certificates issued ...
Cached Biology Technology:Developing Sales Leaders: Benchmarks Reveal Tactics that Will Propel Your Business 2eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services 2eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services 3Phlo Clarifies That Pre-Reverse Split Certificates Are Negotiable in Market Transactions 2
(Date:8/21/2014)... 2014 , WHERE: , San Diego Convention ... 92101 , WHAT: , Invited and platform ... research in human genetics. Examples of sessions include: ... rare genetic variants in health and disease, the ... sensitivity (Saturday, Oct. 18, 5:30-7:30 pm) , Crowdsourced ...
(Date:8/21/2014)... from North Carolina State University have developed a novel ... model has applications for creating new materials as well ... "Our new technique allows us to model much larger ... much more quickly," says Nan Li, lead author of ... in NC State,s Department of Materials Science and Engineering. ...
(Date:8/20/2014)... Knoxville, research finds life can persist in a cold, ... of a team that examined waters and sediments from ... and found the extreme environment supports microbial ecosystems. ... and her colleagues has implications for life in other ... system. The findings are published in the current edition ...
Breaking Biology News(10 mins):American Society of Human Genetics 2014 Annual Meeting 2Researchers develop models to study polyelectrolytes, including DNA and RNA 2University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2
... are thrown away in the European Union each year. However, ... The brown skin and external layers are rich in fibre ... fructans. All of these substances are beneficial to health. ... line with the growing demand for these bulbs. More than ...
... A recent multi-center study determined that women with ... seizures during anovulatory cyclesmenstrual cycles where an egg is ... the study publishing today in Epilepsia , a ... steroids may play a role in GTCS occurrence. ...
... (UPC) have developed a method for evaluating the vulnerability ... method, which has been applied on the Catalan coastline, ... high rate of vulnerability to flooding, while 20% are ... no tool for evaluating coastal storm vulnerability that could ...
Cached Biology News:Dry onion skin has a use 2Greater seizure frequency seen in women with epilepsy during anovulatory cycle 2One-third of central Catalan coast is very vulnerable to storm impact 2
Collected from 8-12 week-old New Zealand or Californian rabbits.,Supplied in lyophilized form....
Silica bead method is an economic method of DNA extraction from agarose...
BD IMag Anti-Mouse CD90.2 (Thy1.2) Particles-MSC 2 x 109 cells...
AgarPlaque Plus Agarose 50 grams...
Biology Products: